BlackRock Inc. raised its position in shares of StemlineTherapeutics Inc. (NASDAQ:STML) by 6.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,406,181 shares of the biopharmaceutical company’s stock after purchasing an additional 83,044 shares during the period. BlackRock Inc. owned about 4.85% of StemlineTherapeutics worth $21,936,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. The Manufacturers Life Insurance Company raised its position in StemlineTherapeutics by 40.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 5,522 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in StemlineTherapeutics by 17.0% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 47,025 shares of the biopharmaceutical company’s stock valued at $734,000 after purchasing an additional 6,825 shares in the last quarter. Raymond James Financial Services Advisors Inc. bought a new stake in StemlineTherapeutics during the 4th quarter valued at $189,000. Bank of New York Mellon Corp raised its position in StemlineTherapeutics by 23.1% during the 4th quarter. Bank of New York Mellon Corp now owns 100,813 shares of the biopharmaceutical company’s stock valued at $1,573,000 after purchasing an additional 18,899 shares in the last quarter. Finally, C WorldWide Group Holding A S raised its position in StemlineTherapeutics by 22.1% during the 4th quarter. C WorldWide Group Holding A S now owns 195,437 shares of the biopharmaceutical company’s stock valued at $3,049,000 after purchasing an additional 35,437 shares in the last quarter. 49.87% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In related news, CEO Ivan Bergstein sold 3,820 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $15.80, for a total transaction of $60,356.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David Gionco sold 4,250 shares of the business’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $13.43, for a total value of $57,077.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 142,378 shares of company stock worth $2,432,553. 15.70% of the stock is owned by company insiders.

STML opened at $17.20 on Tuesday. The firm has a market capitalization of $524.15, a PE ratio of -5.85 and a beta of 0.07. StemlineTherapeutics Inc. has a 12 month low of $7.30 and a 12 month high of $18.75.

StemlineTherapeutics (NASDAQ:STML) last released its quarterly earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.26). StemlineTherapeutics had a negative return on equity of 94.70% and a negative net margin of 4,689.63%. research analysts anticipate that StemlineTherapeutics Inc. will post -2.82 earnings per share for the current year.

Several research firms have recently commented on STML. HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of StemlineTherapeutics in a research report on Friday, February 2nd. ValuEngine raised StemlineTherapeutics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Zacks Investment Research lowered StemlineTherapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 15th. Finally, BidaskClub raised StemlineTherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. StemlineTherapeutics has an average rating of “Buy” and a consensus target price of $31.33.

TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/04/17/stemlinetherapeutics-inc-stml-shares-bought-by-blackrock-inc.html.

StemlineTherapeutics Company Profile

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Institutional Ownership by Quarter for StemlineTherapeutics (NASDAQ:STML)

Receive News & Ratings for StemlineTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StemlineTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.